LGMD is a genetic disease featuring muscle weakness and functional disability due to deficiency of dysferlin protein. Researchers have now identified at least 12 different forms of LGMD. If you have a difficulty in climbing stairs, standing from a squatting position, or raising arms above the head, get ready for genetic testing and Muscle biopsy. And if diagnosed with LGMD, you need not to feel overwhelmed. Currently there are several treatment options for LGMD patient to preserve muscle strength.

Aggressive supportive care is essential to preserve muscle function, maximize functional ability, and prolong life expectancy. Supportive treatment can decrease the complications of the disease. The greatest danger comes from weakening heart muscles or respiratory muscles. Monitoring for heart or breathing complications is recommended. Heart involvement is common. Cardiomyopathy and cardiac arrhythmias may cause clinically significant morbidity.

LGMD can begin at the age between 10 and 30. Both male and female genders are affected equally. Treatment for LGMD is primarily supportive. Yogic exercise and physical therapy are advised to maintain as much muscle strength and joint flexibility as possible. Careful attention to lung and heart health is also required. Ayurvedic treatment is currently effective to address the underlying genetic defects that cause LGMD. There is a variety of research underway targeted at various forms of LGMD. Most significant promise for an effective treatment include “exon skipping” therapy.

Dysferlin deficiency causes two forms of muscular dystrophy: Miyoshi distal myopathy and Limb-Girdle Muscular dystrophy type 2B. Patients with LGMD2B or Miyoshi distal MD may be predisposed to cardiac disease due to fragile muscle fiber. Our current understanding of dystrophies indicates that there are two general approaches to the treatment that offer hope.

The first approach is to develop the technology for effectively replacing the deficient gene into the dystrophic muscles. However, significant technical hurdles have thus far prevented the development of suitable gene therapies. It is important, therefore, to develop alternative therapeutic strategies. The second approach that may lead to treatments of dystrophy is to learn to slow the progress of the deterioration by regulating the large contribution of immune cells to the death of dystrophic muscle. Here Ayurvedic Rasayana treatment is effective.

Mamsagni Rasayana (MR) an investigational Ayurvedic drug is found effective to stop further deterioration of muscles. Patient can notice effect within 6-8 weeks. The medicine taken orally has the potential to address the underlying degenerative process causing destruction of the muscle fibers. Mamsagni Rasayana does not alter the patient’s genetic code or introduce genetic materials into the body. It gives better results if used along with TMP procedure and Yogic support. Ayurvedic ingredients slow down the process of muscle destruction by improving Agni, a key factor required to synthesize cellular proteins.

If you are suffering from LGMD you can fight and win by ayurvedic approach of treatment.

Questions & comments to
AMDS India
6/5 Priyadarshani East, Supela, Bhilai, Chhattisgarh, India